Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 2/20 | 0.61 |
| ▸ | FGFR4 | P22455 | 7/20 | 0.54 |
| ▸ | FGFR1 | P11362 | 9/20 | 0.54 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.53 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.52 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17925405 | 0.89 | JAK3 (0.65) | JAK3FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL19507766 | 0.88 | FGFR2 (0.60) | JAK3FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL19508043 | 0.86 | JAK3 (0.60) | JAK3FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL19507398 | 0.85 | FGFR1 (0.75) | JAK3FGFR1 | |
| SCHEMBL19508319 | 0.84 | FGFR1 (0.59) | JAK3FGFR4FGFR1FGFR2MAPK3 | |
| SCHEMBL19507767 | 0.84 | FGFR4 (0.73) | JAK3FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL19508207 | 0.83 | FGFR1 (0.71) | JAK3FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL19508044 | 0.83 | FGFR1 (0.66) | JAK3FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL19507324 | 0.83 | JAK3 (0.57) | JAK3FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL19507404 | 0.83 | JAK3 (0.57) | JAK3FGFR4FGFR1FGFR2FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10253029-B2 | Dual-warhead covalent inhibitors of FGFR-4 | NEWAVE PHARMACEUTICAL INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-20170305918-A1 | DUAL-WARHEAD COVALENT INHIBITORS OF FGFR-4 | NEWAVE PHARMACEUTICAL INC. | 2017-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305918-A1 | DUAL-WARHEAD COVALENT INHIBITORS OF FGFR-4 | FGFR4, FGFR2, FGFR3 | JAK3 65/4885FGFR4 1/4885FGFR1 4/4885 |
| US-10253029-B2 | Dual-warhead covalent inhibitors of FGFR-4 | FGFR4, FGFR2, FGFR3 | JAK3 65/4885FGFR4 1/4885FGFR1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.